Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: 14 doses of the Moderna COVID-19 vaccines were administered after the 30 day BUD; No adverse event; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (14 doses of the Moderna COVID-19 vaccines were administered after the 30 day BUD) and NO ADVERSE EVENT (No adverse event) in an elderly patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 069H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (14 doses of the Moderna COVID-19 vaccines were administered after the 30 day BUD) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (14 doses of the Moderna COVID-19 vaccines were administered after the 30 day BUD) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (14 doses of the Moderna COVID-19 vaccines were administered after the 30 day BUD).    This case was created for first patient of the 14 patients involved in this case. Concomitant medication was not provided. It was reported that 14 doses of the Moderna COVID-19 vaccines were administered after the 30 day BUD between 15MAY-10JUN2023. Treatment information was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-733933, US-MODERNATX, INC.-MOD-2023-733937, US-MODERNATX, INC.-MOD-2023-733950, US-MODERNATX, INC.-MOD-2023-733945, US-MODERNATX, INC.-MOD-2023-733951, US-MODERNATX, INC.-MOD-2023-733957, US-MODERNATX, INC.-MOD-2023-733962, US-MODERNATX, INC.-MOD-2023-733936, US-MODERNATX, INC.-MOD-2023-733954, US-MODERNATX, INC.-MOD-2023-733959, US-MODERNATX, INC.-MOD-2023-733970, US-MODERNATX, INC.-MOD-2023-733974, US-MODERNATX, INC.-MOD-2023-733979, US-MODERNATX, INC.-MOD-2023-733960 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 14-Jul-2023: Follow up information received and added age group, added batch no. of suspect, added new event of expired vaccine, updated narrative.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-733950: US-MODERNATX, INC.-MOD-2023-733937:Patient 3 US-MODERNATX, INC.-MOD-2023-733933:Patient 2 US-MODERNATX, INC.-MOD-2023-733945:Patient 4 US-MODERNATX, INC.-MOD-2023-733951:Patient 5 US-MODERNATX, INC.-MOD-2023-733957:Patient 6 US-MODERNATX, INC.-MOD-2023-733962:Patient 7 US-MODERNATX, INC.-MOD-2023-733936:Patient 8 US-MODERNATX, INC.-MOD-2023-733954:Patient 9 US-MODERNATX, INC.-MOD-2023-733959:Patient 10 US-MODERNATX, INC.-MOD-2023-733970:Patient 11 US-MODERNATX, INC.-MOD-2023-733974:Patient 12 US-MODERNATX, INC.-MOD-2023-733979:Patient 13 US-MODERNATX, INC.-MOD-2023-733960:Patient 14